HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text (PDF) All Versions of this Article: 288/6/H2744    most recent 00918.2004v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (13) Citing Articles via Google Scholar Google Scholar Articles by Gross, E. R. Articles by Gross, G. J. Search for Related Content PubMed PubMed Citation Articles by Gross, E. R. Articles by Gross, G. J.

Extending the cardioprotective window using a novel -opioid agonist fentanyl isothiocyanate via the PI3-kinase pathway

Medical College of Wisconsin, Department of Pharmacology and Toxicology, Milwaukee, Wisconsin

Submitted 2 September 2004 ; accepted in final form 7 January 2005

	ABSTRACT

TOP ABSTRACT METHODS RESULTS DISCUSSION GRANTS REFERENCES

 
Selective -opioid agonists produce delayed cardioprotection that lasts for 24–48 h in rats; however, the maximum length of the cardioprotective window is unclear. In this study, we attempted to prolong the cardioprotective window using a unique -opioid agonist, fentanyl isothiocyanate (FIT), which binds irreversibly to the -receptor, and determined the role of the phosphatidylinositol 3-kinase (PI3K) pathway as a trigger or end effector of FIT-induced cardioprotection. Initially, male rats were administered FIT (10 µg/kg) 10 min before hearts were subjected to 30 min of ischemia and 2 h of reperfusion followed by infarct size (IS) assessment. Acute FIT administration reduced IS when given before ischemia, 5 min before reperfusion, or 10 s after reperfusion compared with control. IS reduction also occurred following a single dose of FIT at 48, 72, 96, and 120 h after administration vs. control, with the maximum effect observed at 96 h. FIT-induced IS reduction at 96 h was completely abolished when the irreversible PI3K inhibitor wortmannin (15 µg/kg) was given before FIT during the trigger phase; however, the effect was only partially abrogated when wortmannin was given 96 h later. These data suggest that FIT has a prolonged cardioprotective window greater than that of any previously described cardioprotective agent that requires PI3K primarily in the trigger phase but also partially, as a mediator or end effector.

delayed cardioprotection; phosphatidylinositol 3-kinase; opioids; BW373U86; postconditioning

Exogenous administration of selective -opioid agonists produces a reduction of infarct size when given acutely, before ischemia or immediately before reperfusion, and these compounds also produce a delayed effect when given 24–48 h before index ischemia (10, 14, 15, 25, 31, 37). The longest known window of cardioprotection by opioids occurred after TAN-67 administration, which lasted for 48 h; however, the duration of opioid-induced cardioprotection has not been tested with other -opioid agonists (10).

Fentanyl is a potent µ-opioid receptor agonist that has been shown to reduce infarct size in rats via a -opioid-dependent mechanism; however, it failed to improve postischemic mechanical function from stunning (4, 21, 22). Addition of cyanide to fentanyl, generating the compound fentanyl isothiocyanate (FIT), creates a selective, irreversible -opioid agonist that alkylates the -receptor without cross-reactivity with the µ-receptor (7, 36) (Fig. 1). The cardioprotective properties of FIT have not been previously determined.

View larger version (8K): [in this window] [in a new window]   Fig. 1. Molecular structure of fentanyl and the fentanyl derivative, fentanyl isothiocyanate (FIT). Addition of a cyanide to fentanyl generates an irreversible -opioid agonist.

Therefore, we examined the dose, length of the cardioprotective window, and dependence of the PI3K pathway on FIT-induced infarct size reduction in rats. We further examined whether FIT induces the activation of the PI3K pathway.

	METHODS

TOP ABSTRACT METHODS RESULTS DISCUSSION GRANTS REFERENCES

 
The experimental procedures and protocols used in this study were reviewed and approved by the Animal Care and Use Committee of the Medical College of Wisconsin and conformed with the National Institutes of Health Guide for the Care and Use of Laboratory Animals.

Male Sprague-Dawley rats (215–300 g) were obtained from Harlan and used for an in vivo anesthetized, intact rat model of ischemia and reperfusion consisting of 30 min of ischemia and 2 h of reperfusion. The general surgical protocols for acute and delayed infarct size studies, including the determination of infarct size, have been described previously in detail (13). Hemodynamics, including heart rate, mean arterial pressure, and rate-pressure product, were quantified during baseline, 15 min into ischemia, and at 2 h of reperfusion.

Pharmacological agents. The agents used for this study included FIT {N-1-[2-(4-isothiocyanatophenyl)ethyl]-4-piperidinyl-N-phenylpropanamide; Tocris}, BW373U86 (Ardent), and wortmannin (Sigma). FIT was dissolved in 95% ethanol, whereas BW373U86 and wortmannin were dissolved in DMSO.

Acute infarct size studies. For the acute infarct size studies, FIT was administered 10 min before ischemia at a range of doses (1–300 µg/kg) and infarct size was determined. Additional rats received vehicle (95% ethanol) 10 min before ischemia. The optimal dose of FIT necessary to produce the maximal reduction of infarct size compared with the vehicle-treated group was determined in this series of experiments.

A second series of experiments determined whether FIT (10 µg/kg) administered 5 min before reperfusion or 10 s after reperfusion could reduce infarct size equal to that measured when FIT was administered 10 min before ischemia.

Delayed infarct size studies. Rats were treated with a single intravenous dose of FIT (10 µg/kg) via tail vein injection. Animals were provided with ample food and water and allowed to recover for time periods ranging from 48 to 144 h. An additional series of rats was treated with a single intravenous dose of BW373U86 (10 µg/kg), another selective -opioid agonist, and allowed to recover for 96 h. Rats were then subjected to 30 min of ischemia and 2 h of reperfusion, followed by infarct size assessment.

A second series of rats was treated with the PI3K inhibitor wortmannin (15 µg/kg) 90 min before FIT (10 µg/kg) administration to determine whether triggering of FIT-induced infarct size reduction is dependent on the PI3K pathway. Rats were allowed to recover for 96 h and then subjected to ischemia-reperfusion and infarct size assessment. To determine the contribution of the PI3K pathway as a mediator or end effector of FIT-induced infarct size reduction, we administered FIT (10 µg/kg) and allowed rats to recover for 96 h. Wortmannin was administered 10 min before index ischemia, and the standard ischemia-reperfusion and infarct size protocols were conducted.

Statistical significance. All values are denoted as means ± SE. For the hemodynamics and infarct size studies, statistical significance was determined by performing a one-way ANOVA with Bonferroni's correction for multiplicity. A significant difference was indicated at a P value <0.001 or <0.01.

	RESULTS

TOP ABSTRACT METHODS RESULTS DISCUSSION GRANTS REFERENCES

 
We used 131 rats to perform 119 successful experiments. Twelve rats were omitted because of ventricular fibrillation during reperfusion (3), a suture breaking during negative staining for the normal zone (2), or failure to administer the full drug dose into the tail vein because of the rat flicking its tail (7).

Hemodynamics. Heart rate, mean arterial pressure, and rate-pressure product for the acute infarct size experiments showed significant differences in baseline heart rate between the vehicle-treated group and the experimental group when FIT was administered 10 s after reperfusion. Significant differences in mean arterial pressure were also present between the vehicle-treated group and the experimental group when FIT was administered at 300 µg/kg before ischemia and when FIT was administered 5 min before reperfusion. No other significant differences were seen in hemodynamics for the acute infarct size studies (Table 1).

View larger version (10K): [in this window] [in a new window]   Fig. 2. Infarct size (IF) expressed as a percentage of the area at risk (AAR) in rats (n = 6/group) treated with vehicle (V) or FIT (1–300 µg/kg) 10 min before ischemia. Values are means ± SE. *P < 0.01; +P < 0.001 vs. vehicle.

View larger version (8K): [in this window] [in a new window]   Fig. 3. Infarct size expressed as a percentage of the area at risk in rats (n = 6/group) treated with vehicle or FIT (10 µg/kg). FIT was administered either 10 min before ischemia (pre-occ), 5 min before reperfusion (pre-rep), or 10 s after reperfusion (post-rep). Values are means ± SE. *P < 0.01; +P < 0.001 vs. vehicle.

View larger version (10K): [in this window] [in a new window]   Fig. 4. Infarct size expressed as a percentage of the area at risk in rats (n = 5–6/group) treated with vehicle or FIT (10 µg/kg). Experiments were performed at times ranging from 48 to 144 h after FIT administration. Values are means ± SE. *P < 0.01; +P < 0.001 vs. vehicle. P < 0.001, experiments performed 96 h after FIT administration vs. other experimental groups.

View larger version (12K): [in this window] [in a new window]   Fig. 5. Infarct size expressed as a percentage of the area at risk in rats (n = 6/group) treated with ethanol (EtOH) or DMSO vehicle or FIT (10 µg/kg) in the presence or absence of the phosphatidylinositol 3-kinase (PI3K) inhibitor wortmannin. Wortmannin was administered 90 min before FIT administration during the trigger phase [W(T)+FIT] or 10 min before ischemia during the end-effector phase [W(E)+FIT] or administered alone [W(T)] or 96 h later [W(E)]. Values are means ± SE. +P < 0.001 vs. vehicle. P < 0.001, wortmannin administered with FIT as a trigger vs. wortmannin administered with FIT as an end-effector.

	DISCUSSION

TOP ABSTRACT METHODS RESULTS DISCUSSION GRANTS REFERENCES

Recently, the ability to protect the myocardium after reperfusion with brief, repetitive cycles of ischemia and reperfusion, coined postconditioning, has been shown to occur in dogs and rats (23, 44). Pharmacological agents also have shown the ability to reduce infarct size when administered at reperfusion, including adenosine and insulin (18, 43). Our data suggest that the efficacy of the selective -opioid agonist FIT to postcondition the myocardium reduces infarct size to an extent similar to that observed when FIT was administered either before ischemia or immediately before reperfusion. Interestingly, in a different study, morphine administered at 10 s after reperfusion failed to postcondition the myocardium (14). The differences in the ability of morphine and FIT to postcondition the myocardium may be caused by the greater selectivity and preference of FIT to bind to the -opioid receptor compared with morphine. Morphine may have less selectivity for the -opioid receptor (16).

The ability of FIT to reduce infarct size up to 120 h after administration makes it the first pharmacological agent known to extend the window of cardioprotection >72 h. Interestingly, adenosine is the only pharmacological agent previously shown to cause cardioprotection up to 72 h as assessed by infarct size (3). Both the K_ATP channel opener diazoxide and -opioid agonist TAN-67 have a significantly shorter window of cardioprotection, lasting 24 and 48 h, respectively (10, 38). Human studies with tissue taken from the right atrial appendage of patients with triple vessel coronary artery disease have shown that both adenosine and phenylephrine can cause protection from simulated ischemia-reperfusion up to 72 h after administration (27). The selective -opioid agonists BW373U86, SNC-80, and TAN-67 all produced similar infarct size reduction in previous studies at 24 h, with the infarct size reduction comparable to FIT-induced infarct size reduction at 96 h (31, 32). Interestingly, in the present study, BW373U86 (10 µg/kg) also reduced infarct size 96 h after administration, suggesting that the extended window of cardioprotection is perhaps a common mechanism among certain selective -opioid agonists. Collectively, these data suggest that pharmacological agents have different windows of protection that perhaps could be based on receptor selectivity and the dose of pharmacological agent administered.

The ability of FIT (10 µg) to cause acute cardioprotection is more efficacious, on the basis of the dose administered, compared with other -selective opioid agonists tested, such as BW373U86 (1 mg/kg) or TAN-67 (30 mg/kg), or nonselective agonists, such as morphine (0.3 mg/kg) when delivered as a bolus injection (10, 15). As an infarct size-reducing agent, the lower dose of FIT is just as effective as morphine or SNC-121 but not as effective as TAN-67. The greater infarct size reduction ability of TAN-67 may be due to 1) the generous dose used of TAN-67 (30 mg/kg), perhaps causing nonspecific effects to enhance infarct size reduction, 2) the differences in rat species (Wistar vs. Sprague-Dawley), or 3) the timing of the doses administered (1 h vs. 10 min before ischemia) (10).

An additional reason why differences in efficacy and infarct size-reducing ability are present for FIT compared with other -opioid agonists and morphine may be explained by the binding properties to the -opioid receptor for FIT compared with those to the other opioid agonists. A derivative of FIT, SUPERFIT, previously was shown to target the first intracellular loop to the middle of the third transmembrane helix (45). This region is different than the area targeted by the other -opioid agonists, BW373U86, SNC-121, and TAN-67, which target the fifth and seventh transmembrane regions of the third extracellular loop of the -opioid receptor (29). This could explain why FIT, as a delayed cardioprotective agent, has a greater reduction of infarct size after 96 h compared with BW373U86.

The inability of FIT to be protective at the higher doses studied (100 and 300 µg/kg) is not surprising, because previous studies have shown that other -opioid agonists produce a similar dose-dependent profile of infarct size reduction vs. -opioid agonist dose (31). The reason why higher doses of opioids are not protective is unknown. However, after significant activation of opioid receptors, negative feedback systems, which include cholecystokinin and excitatory opioid receptors coupled through G_s, are activated (41). Hence, the ability for opioids to induce cardioprotection may be based on the careful balance between exogenous opioid administration and endogenous antiopioid systems.

The ability of FIT to produce the maximal effect after 96 h, which is only submaximal after 48 or 72 h, also may be based on the balance between exogenous opioid administration and endogenous antiopioid systems. More studies concerning the time-dependent differences in infarct size for this agent need to be conducted. However, the time-dependent response on infarct size is not unique, because both -selective opioids and K_ATP channel openers produce a similar outcome of infarct size over time (8, 36).

The extended window of protection provided by FIT provides a significant advantage over IP, for which attempts in all species have failed to shown an extension of protection >72 h (2). The delayed protection by FIT at 96 h also displayed an infarct size reduction greater than the acute protective effects of FIT. These findings also suggest that opioids induce delayed protection perhaps by a different mechanism than IP, because previous studies have shown that delayed protection by IP is significantly less than the acute IP-induced cardioprotective effect (2).

For opioid-induced delayed cardioprotection, previous characterization has shown that important components of the trigger phase include the sarcolemmal K_ATP channel, MEK1/2, and p38, with components of the end effector being the mitochondrial K_ATP channel, 12-lipoxygenase, cyclooxygenase-2 (COX-2), and inducible nitric oxide synthase (iNOS) (11, 25, 31–33, 37). Traditionally, IP-induced delayed cardioprotection has exhibited an iNOS-dependent mechanism as an end effector at 24 h (5). Interestingly, the same laboratory recently showed that 72 h after IP, neuronal NOS but not iNOS was identified as the end effector (42). These data indicate the importance of developing models with an extended delayed cardioprotective window to discern the components involved in the trigger, mediator, and end-effector phases of cardioprotection. The length of a FIT- or BW373U86-induced window of cardioprotection will be a valuable tool in discerning the mechanisms involved in opioid-induced delayed cardioprotection.

Mechanistically, we found that the trigger phase of FIT-induced delayed cardioprotection appears to be dependent on the PI3K pathway to initiate pathways that are downstream of PI3K to be cardioprotective. These results are similar to those found in a previous study of delayed IP, where IP-induced delayed cardioprotection at 24 h was found to be abolished by pretreatment with wortmannin (24). Another salient finding is that the PI3K pathway is also required as a partial end effector of opioid-induced delayed cardioprotection, because wortmannin partially abrogated FIT-induced cardioprotection when administered 96 h after FIT, just before index ischemia. The contribution of PI3K as an end effector for IP is also unknown.

Previously, phosphorylation of both Akt and GSK-, downstream mediators of PI3K, have been shown to be important in cardioprotection (20, 30). Addition of a constitutively active adenoviral Akt to the myocardium can cause protection and infarct size reduction 24–48 h after delivery (28, 30). IGF-1 and IP also have been shown to cause cardioprotection by Akt phosphorylation; both cardioprotection and Akt phosphorylation were abrogated in the presence of wortmannin (12, 24). Akt may act as a trigger of cardioprotection via multiple protein interactions, including its ability to induce transcriptional and antiapoptotic proteins, which includes the phosphorylation of GSK- (17).

Phosphorylation of GSK-, which produces its inactivation, previously has been shown to be important in mediating both IP- and opioid-induced infarct size reduction, with this cardioprotection mimicked by selective GSK inhibitors (15, 40). Interestingly, GSK- phosphorylation may be a valuable convergence point for multiple cellular pathways including PI3K, protein kinase C, and targets of rapamycin-dependent pathways activated by both pharmacological agents and IP (15, 20, 40). It is also evident in nonmycoardial cells that GSK- inhibition subsequently results in the activation of many diverse cellular signaling pathways, including the putative substrates heat shock factor-1 and NF-B (19). These two substrates are of interest because both lead to induction of proteins found to be end effectors of delayed cardioprotection, such as heat shock protein-70, COX-2, and iNOS (1).

One of the established end effectors in opioid-induced delayed cardioprotection is NF-B-induced COX-2 (26, 34, 37). Interestingly, COX-2 was recently shown to be regulated by the PI3K pathway in a variety of nonmyocardial cell lines (6, 26, 35, 39). Inhibition of GSK- by lithium has been shown to elevate COX-2 expression and COX-2 promoter activity, whereas conversely, expression of a dominant negative Akt mutant or wild-type GSK- suppressed COX-2 promoter activity (39). COX-2 induction by either the selective ATP-sensitive GSK- inhibitors or lithium also was found to be mediated by increased NF-B activity (35). Therefore, a possible link between the trigger and the induction of the end-effector proteins may involve GSK- phosphorylation, and this cause and effect needs to be studied in more detail.

Our study is not without potential limitations, including the recognition that this is the first in vivo study conducted for FIT. Therefore, the half-life of FIT is unknown, and it is feasible that the irreversible nature of FIT maintains the ability of this agent to cause the extended protection. Because of the irreversible nature of FIT, we also used an irreversible antagonist of the PI3K pathway, wortmannin. Hence, we are confident that for our mechanistic studies, PI3K was inhibited for as long as FIT was irreversibly bound to the -opioid receptor.

In conclusion, we have found that a novel -selective agonist, FIT, has a cardioprotective window that extends from reperfusion to 120 h after administration. The trigger and end-effector phases of FIT-induced cardioprotection are also PI3K pathway dependent.

	GRANTS

TOP ABSTRACT METHODS RESULTS DISCUSSION GRANTS REFERENCES

 
This work was supported by National Heart, Lung, and Blood Institute Grants HL-08311 and HL-074314 (to G. J. Gross) and an American Heart Predoctoral Fellowship (Northland Affiliate) (to E. R. Gross) and Postdoctoral Fellowship (Northland Affiliate) (to J. N. Peart).

	FOOTNOTES

 

Address for reprint requests and other correspondence: G. J. Gross, Medical College of Wisconsin, Dept. of Pharmacology and Toxicology, 8701 Watertown Plank Road, Milwaukee, WI 53226 (E-mail: ggross{at}mcw.edu)

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

	REFERENCES

TOP ABSTRACT METHODS RESULTS DISCUSSION GRANTS REFERENCES

 

1. Baines CP, Pass JM, and Ping P. Protein kinases and kinase-modulated effectors in the late phase of ischemic preconditioning. Basic Res Cardiol 96: 207–218, 2001.[CrossRef][ISI][Medline]
2. Baxter GF and Ferdinandy P. Delayed preconditioning of myocardium: current perspectives. Basic Res Cardiol 96: 329–344, 2001.[CrossRef][ISI][Medline]
3. Baxter GF and Yellon DM. Time course of delayed myocardial protection after transient adenosine A1-receptor activation in the rabbit. J Cardiovasc Pharmacol 29: 631–638, 1997.[CrossRef][ISI][Medline]
4. Benedict PE, Benedict MB, Su TP, and Bolling SF. Opiate drugs and delta-receptor-mediated myocardial protection. Circulation 100: II357–II360, 1999.[Medline]
5. Bolli R, Dawn B, Tang XL, Qiu Y, Ping P, Xuan YT, Jones WK, Takano H, Guo Y, and Zhang J. The nitric oxide hypothesis of late preconditioning. Basic Res Cardiol 93: 325–338, 1998.[CrossRef][ISI][Medline]
6. Bradbury DA, Corbett L, and Knox AJ. PI 3-kinase and MAP kinase regulate bradykinin induced prostaglandin E₂ release in human pulmonary artery by modulating COX-2 activity. FEBS Lett 560: 30–34, 2004.[CrossRef][ISI][Medline]
7. Burke TR Jr, Bajwa BS, Jacobson AE, Rice KC, Streaty RA, and Klee WA. Probes for narcotic receptor mediated phenomena. 7. Synthesis and pharmacological properties of irreversible ligands specific for mu or delta opiate receptors. J Med Chem 27: 1570–1574, 1984.[CrossRef][ISI][Medline]
8. Chen M, Zhou JJ, Kam KW, Qi JS, Yan WY, Wu S, and Wong TM. Roles of K_ATP channels in delayed cardioprotection and intracellular Ca²⁺ in the rat heart as revealed by -opioid receptor stimulation with U50488H. Br J Pharmacol 140:750–758, 2003.[CrossRef][ISI][Medline]
9. Ebrahim Z, Yellon DM, and Baxter GF. Bradykinin elicits "second window" myocardial protection in rat heart through an NO-dependent mechanism. Am J Physiol Heart Circ Physiol 281: H1458–H1464, 2001.[Abstract/Free Full Text]
10. Fryer RM, Hsu AK, Eells JT, Nagase H, and Gross GJ. Opioid-induced second window of cardioprotection: potential role of mitochondrial K_ATP channels. Circ Res 84: 846–851, 1999.[Abstract/Free Full Text]
11. Fryer RM, Hsu AK, and Gross GJ. ERK and p38 MAP kinase activation are components of opioid-induced delayed cardioprotection. Basic Res Cardiol 96: 136–142, 2001.[CrossRef][ISI][Medline]
12. Fujio Y, Nguyen T, Wencker D, Kitsis RN, and Walsh K. Akt promotes survival of cardiomyocytes in vitro and protects against ischemia-reperfusion injury in mouse heart. Circulation 101: 660–667, 2000.[Abstract/Free Full Text]
13. Gross ER, Peart JN, Hsu AK, Grover GJ, and Gross GJ. K_ATP opener-induced delayed cardioprotection: involvement of sarcolemmal and mitochondrial K_ATP channels, free radicals and MEK1/2. J Mol Cell Cardiol 35: 985–992, 2003.[CrossRef][ISI][Medline]
14. Gross ER, Hsu AK, and Gross GJ. Acute aspirin treatment abolishes, whereas acute ibuprofen treatment enhances morphine-induced cardioprotection: role of 12-lipoxygenase. J Pharmacol Exp Ther 310: 185–191, 2004.[Abstract/Free Full Text]
15. Gross ER, Hsu AK, and Gross GJ. Opioid-induced cardioprotection occurs via glycogen synthase kinase inhibition during reperfusion in intact rat hearts. Circ Res 94: 960–966, 2004.[Abstract/Free Full Text]
16. Gross GJ. Role of opioids in acute and delayed preconditioning. J Mol Cell Cardiol 35: 709–718, 2003.[CrossRef][ISI][Medline]
17. Hausenloy DJ and Yellon DM. New directions for protecting the heart against ischaemia-reperfusion injury: targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway. Cardiovasc Res 61: 448–460, 2004.[Abstract/Free Full Text]
18. Jonassen AK, Sack MN, Mjos OD, and Yellon DM. Myocardial protection by insulin at reperfusion requires early administration and is mediated via Akt and p70s6 kinase cell-survival signaling. Circ Res 89: 1191–1198, 2001.[Abstract/Free Full Text]
19. Jope RS and Johnson GV. The glamour and gloom of glycogen synthase kinase-3. Trends Biochem Sci 29: 95–102, 2004.[CrossRef][ISI][Medline]
20. Juhaszova M, Zorov DB, Kim SH, Pepe S, Fu Q, Fishbein KW, Ziman BD, Wang S, Ytrehus K, Antos CL, Olson EN, and Sollott SJ. Glycogen synthase kinase-3 mediates convergence of protection signaling to inhibit the mitochondrial permeability transition pore. J Clin Invest 113: 1535–1549, 2004.[CrossRef][ISI][Medline]
21. Kato R, Ross S, and Foex P. Fentanyl protects the heart against ischaemic injury via opioid receptors, adenosine A₁ receptors and K_ATP channel linked mechanisms in rats. Br J Anaesth 84: 204–214, 2000.[Abstract/Free Full Text]
22. Kato R and Foex P. Fentanyl reduces infarction but not stunning via -opioid receptors and protein kinase C in rats. Br J Anaesth 84: 608–614, 2000.[Abstract/Free Full Text]
23. Kin H, Zhao ZQ, Sun HY, Wang NP, Corvera JS, Halkos ME, Kerendi F, Guyton RA, and Vinten-Johansen J. Postconditioning attenuates myocardial ischemia-reperfusion injury by inhibiting events in the early minutes of reperfusion. Cardiovasc Res 62: 74–85, 2004.[Abstract/Free Full Text]
24. Kis A, Yellon DM, and Baxter GF. Second window of protection following myocardial preconditioning: an essential role for PI3 kinase and p70S6 kinase. J Mol Cell Cardiol 35: 1063–1071, 2003.[CrossRef][ISI][Medline]
25. Kodani E, Xuan YT, Shinmura K, Takano H, Tang XL, and Bolli R. -Opioid receptor-induced late preconditioning is mediated by cyclooxygenase-2 in conscious rabbits. Am J Physiol Heart Circ Physiol 283: H1943–H1957, 2002.[Abstract/Free Full Text]
26. Lee HY, Suh YA, Kosmeder JW, Pezzuto JM, Hong WK, and Kurie JM. Deguelin-induced inhibition of cyclooxygenase-2 expression in human bronchial epithelial cells. Clin Cancer Res 10: 1074–1079, 2004.[Abstract/Free Full Text]
27. Loubani M, Hassouna A, and Galinanes M. Delayed preconditioning of the human myocardium: signal transduction and clinical implications. Cardiovasc Res 61: 600–609, 2004.[Abstract/Free Full Text]
28. Matsui T, Tao J, del Monte F, Lee KH, Li L, Picard M, Force TL, Franke TF, Hajjar RJ, and Rosenzweig A. Akt activation preserves cardiac function and prevents injury after transient cardiac ischemia in vivo. Circulation 104: 330–335, 2001.[Abstract/Free Full Text]
29. Meng F, Ueda Y, Hoverstten MT, Thompson RC, Taylor L, Watson SJ, and Akil H. Mapping the receptor domains critical for binding selectivity of -opioid receptor ligands. Eur J Pharmacol 311: 285–292, 1996.[CrossRef][ISI][Medline]
30. Miao W, Luo Z, Kitsis RN, and Walsh K. Intracoronary, adenovirus-mediated Akt gene transfer in heart limits infarct size following ischemia-reperfusion injury in vivo. J Mol Cell Cardiol 32: 2397–2402, 2000.[CrossRef][ISI][Medline]
31. Patel HH, Hsu A, Moore J, and Gross GJ. BW373U86, a opioid agonist, partially mediates delayed cardioprotection via a free radical mechanism that is independent of opioid receptor stimulation. J Mol Cell Cardiol 33: 1455–1465, 2001.[CrossRef][ISI][Medline]
32. Patel HH, Hsu AK, Peart JN, and Gross GJ. Sarcolemmal K_ATP channel triggers opioid-induced delayed cardioprotection in the rat. Circ Res 91: 186–188, 2002.[Abstract/Free Full Text]
33. Patel HH, Fryer RM, Gross ER, Bundey RA, Hsu AK, Isbell M, Eusebi LO, Jensen RV, Gullans SR, Insel PA, Nithipatikom K, and Gross GJ. 12-Lipoxygenase in opioid-induced delayed cardioprotection: gene array, mass spectrometric, and pharmacological analyses. Circ Res 92: 676–682, 2003.[Abstract/Free Full Text]
34. Patel HH, Hsu AK, and Gross GJ. COX-2 and iNOS in opioid-induced delayed cardioprotection in the intact rat. Life Sci 75: 129–140, 2004.[CrossRef][ISI][Medline]
35. Rao R, Hao CM, and Breyer MD. Hypertonic stress activates glycogen synthase kinase 3-mediated apoptosis of renal medullary interstitial cells, suppressing an NFB-driven cyclooxygenase-2-dependent survival pathway. J Biol Chem 279: 3949–3955, 2004.[Abstract/Free Full Text]
36. Rice KC, Jacobson AE, Burke TR Jr, Bajwa BS, Streaty RA, and Klee WA. Irreversible ligands with high selectivity toward delta and mu opiate receptors. Science 220: 314–316, 1983.[Abstract/Free Full Text]
37. Shinmura K, Nagai M, Tamaki K, Tani M, and Bolli R. COX-2-derived prostacyclin mediates opioid-induced late phase of preconditioning in isolated rat hearts. Am J Physiol Heart Circ Physiol 283: H2534–H2543, 2002.[Abstract/Free Full Text]
38. Takashi E, Wang Y, and Ashraf M. Activation of mitochondrial K_ATP channel elicits late preconditioning against myocardial infarction via protein kinase C signaling pathway. Circ Res 85: 1146–1153, 1999.[Abstract/Free Full Text]
39. Tang Q, Gonzales M, Inoue H, and Bowden GT. Roles of Akt and glycogen synthase kinase 3 in the ultraviolet B induction of cyclooxygenase-2 transcription in human keratinocytes. Cancer Res 61: 4329–4332, 2001.[Abstract/Free Full Text]
40. Tong H, Imahashi K, Steenbergen C, and Murphy E. Phosphorylation of glycogen synthase kinase-3 during preconditioning through a phosphatidylinositol-3-kinase-dependent pathway is cardioprotective. Circ Res 90: 377–379, 2002.[Abstract/Free Full Text]
41. Waldhoer M, Bartlett SE, and Whistler JL. Opioid receptors. Annu Rev Biochem 73: 953–990, 2004.[CrossRef][ISI][Medline]
42. Wang Y, Kodani E, Wang J, Zhang SX, Takano H, Tang XL, and Bolli R. Cardioprotection during the final stage of the late phase of ischemic preconditioning is mediated by neuronal NO synthase in concert with cyclooxygenase-2. Circ Res 95: 84–91, 2004.[Abstract/Free Full Text]
43. Yang XM, Krieg T, Cui L, Downey JM, and Cohen MV. NECA and bradykinin at reperfusion reduce infarction in rabbit hearts by signaling through PI3K, ERK, and NO. J Mol Cell Cardiol 36: 411–421, 2004.[CrossRef][ISI][Medline]
44. Zhao ZQ, Corvera JS, Halkos ME, Kerendi F, Wang NP, Guyton RA, and Vinten-Johansen J. Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. Am J Physiol Heart Circ Physiol 285: H579–H588, 2003.[Abstract/Free Full Text]
45. Zhu J, Yin J, Law PY, Claude PA, Rice KC, Evans CJ, Chen C, Yu L, and Liu-Chen LY. Irreversible binding of cis-(+)-3-methylfentanyl isothiocyanate to the opioid receptor and determination of its binding domain. J Biol Chem 271:1430–1434, 1996.[Abstract/Free Full Text]

This article has been cited by other articles:

				H. H. Patel and R. S. Ostrom An orphan GPCR finds a home in the heart Am J Physiol Heart Circ Physiol, August 1, 2008; 295(2): H479 - H481. [Full Text] [PDF]

				A. J. Zatta, H. Kin, D. Yoshishige, R. Jiang, N. Wang, J. G. Reeves, J. Mykytenko, R. A. Guyton, Z.-Q. Zhao, J. L. Caffrey, et al. Evidence that cardioprotection by postconditioning involves preservation of myocardial opioid content and selective opioid receptor activation Am J Physiol Heart Circ Physiol, March 1, 2008; 294(3): H1444 - H1451. [Abstract] [Full Text] [PDF]

				C. K. Yu, Y.-H. Li, G. T. C. Wong, T. M. Wong, and M. G. Irwin Remifentanil preconditioning confers delayed cardioprotection in the rat Br. J. Anaesth., November 1, 2007; 99(5): 632 - 638. [Abstract] [Full Text] [PDF]

				E. R. Gross and G. J. Gross Ligand triggers of classical preconditioning and postconditioning Cardiovasc Res, May 1, 2006; 70(2): 212 - 221. [Abstract] [Full Text] [PDF]

				N. Smart, M. H. Mojet, D. S. Latchman, M. S. Marber, M. R. Duchen, and R. J. Heads IL-6 induces PI 3-kinase and nitric oxide-dependent protection and preserves mitochondrial function in cardiomyocytes Cardiovasc Res, January 1, 2006; 69(1): 164 - 177. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) All Versions of this Article: 288/6/H2744    most recent 00918.2004v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (13) Citing Articles via Google Scholar Google Scholar Articles by Gross, E. R. Articles by Gross, G. J. Search for Related Content PubMed PubMed Citation Articles by Gross, E. R. Articles by Gross, G. J.